Axol Bioscience Ltd.’s Post

Our axoCells™ Astrocytes line (ax0704) is designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with our axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Click here to read more about this product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02H3-SF0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02H3Rb_0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

📣 New product alert- the fastest and most affordable human iPSC-derived astrocytes on the market! 📣 We're delighted to announce our new axoCells™ Astrocytes line (ax0704) designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with this new axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our new axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Bolstered by our world-leading ISO 9001-accredited manufacturing processes, we are delighted to pass on further cost savings to you. Our new ax0704 astrocytes are cheaper than previous astrocytes and are priced at just £660 / $830 / €770 per vial (1 million cells)- the best price on the market! Click here to read more about this new product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02yPN3Q0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02yPMGC0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

📣 New product alert- the fastest and most affordable human iPSC-derived astrocytes on the market! 📣 We're delighted to announce our new axoCells™ Astrocytes line (ax0704) designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with this new axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our new axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Bolstered by our world-leading ISO 9001-accredited manufacturing processes, we are delighted to pass on further cost savings to you. Our new ax0704 astrocytes are cheaper than previous astrocytes and are priced at just £660 / $830 / €770 per vial (1 million cells)- the best price on the market! Click here to read more about this new product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02yPN8l0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02yPQHX0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

Next week is #AAIC24! Join our Co-Founder & CEO, Damian Wheeler, PhD, and expert Chase Redd as they present tools, technologies, and #3Dhistology techniques that are furthering Alzheimer's research. We're showcasing two posters: • Poster #841 (Abstract ID 95666), “Brain-Wide Cellular-Resolution Measurement of Antibody Therapeutic Biodistribution” on Sunday, July 28th • Poster #874 (Abstract ID 95690), “Brain-Wide Cellular-Resolution Quantification of Amyloid Plaques and Microglia in AD Model Mice” on Tuesday, July 30th These posters highlight how tissue clearing and light sheet microscopy methods enable unbiased, brain-wide analysis of therapeutics and neuroinflammation, offering cellular resolution measurements of BBB penetration of antibody therapeutics and providing AI-powered quantification of #amyloidplaques and #microglia across entire mouse brains. Join us at #AAIC2024 to learn more about how #tissueclearing and #lightsheet #microscopy advances can accelerate pre-clinical CNS therapeutic development and shape the future of #AlzheimersDisease research. We're looking forward to engaging with fellow researchers and advancing our collective understanding of Alzheimer's disease. #Neuroscience, #AlzheimersResearch, #Biotech, #Innovation, #CNSDrugDevelopment, Alzheimer's Association®

🌟 𝐈𝐧𝐌𝐞𝐝'𝐬 𝐈𝐍𝐌-𝟗𝟎𝟏: 𝐀 𝐍𝐞𝐰 𝐇𝐨𝐩𝐞 𝐟𝐨𝐫 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 💡 𝗜𝗻 𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟰, InMed Pharmaceuticals recently released preclinical data indicating its proprietary, #smallmolecule compound, INM-901, targets multiple #biological pathways associated with #Alzheimer’sdisease. Among the most interesting data from the recent reports, was the ability of its compound to extend the length of #neurites, which may indicate enhanced neuronal functioning in the #brain and the potential to reverse the #damage caused by Alzheimer’s disease. The company was encouraged with these breakthrough preclinical results and will be advancing the development of the INM-901 Alzheimer’s disease program. InMed's preclinical model of Alzheimer's disease, which is well characterised, showed encouraging outcomes in both in vitro and in vivo trials. The study claims that it might encourage neurite growth and extension, or neutogenesis, a crucial aspect of cell-to-cell communication. In in-vivo experiments, INM-901 also revealed decreased neuroinflammation and improved behaviour, memory, and cognitive function. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉:https://bit.ly/46jbV2x #AlzheimersTreatment #InnovativeTherapy #AlzheimersResearch #MultiFactorialApproach #BreakthroughMedicine #NeuroScience #AlzheimersHope #prophecymarketinsights

In our latest application report, we used genetically engineered Granulin R493 frontotemporal dementia (FTD) hiPSC-derived neurons to correlate ion channel function (Kv, Nav, and AMPA) to neuron excitability. Learn more and read the new application report here: https://lnkd.in/ezxKfkKk Using QPatch automated patch clamp, we explored how altered ion channel dynamics and current densities may modulate neuron excitability and contribute to FTD-related dysfunction. This research offers new insights into handling and recording hiPSC-derived neurons using automated patch clamp, including assays for exploring the specific neurodegenerative mechanisms and potential therapeutic targets in FTD. Are you attending Neuroscience 2024 in Chicago starting this week? Stop by our booth #745 and visit our poster PSTR269.18 / C3 in MCP Hall A to learn more about our latest research with hiPSC-derived dementia neurons. For more info on where to find us on SfN 2024, click here: https://lnkd.in/dw2h44zw The application report and related research was developed by Sophion Bioscience in collaboration with FUJIFILM Cellular Dynamics, Inc. #SfN2024 #FTD #Dementia #hiPSC #StemCells #QPatch #AutomatedPatchClamp #IonChannels #DrugDiscovery #Electrophysiology #Sophion

In #BrainAwarenessWeek, Sophion Bioscience's Kadla Røskva Rosholm & Stefania Karatsiompani presented a poster at the 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 𝗶𝗻 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 in Tübingen, Germany today. The poster highlights our latest advances using #AutomatedPatchClamp for high-throughput characterization and comparison of FUJIFILM Cellular Dynamics' 'healthy' (WT) and frontotemporal #dementia #iPSC derived iCell® Induced Excitatory Neurons. You can download the poster if you missed the poster presentation, click here: https://lnkd.in/dm38U_Jv Induced pluripotent stem cells have great potential in the generation and characterization of neuronal subtypes as well as the investigation of neurological disease models. However, in practice, the intercellular variability in a population of iPSC-derived neurons, in combination with the low-throughput nature of manual electrophysiological experiments, have made such studies challenging. To learn more about Sophion's #AutomatedPatchClamp technology, visit our poster no. 29 tomorrow or book a meeting with us during the conference, click here: https://lnkd.in/ev5faFbN. #iPSC #StemCells #Qube384 #QPatch #QPatchCompact #AutomatedPatchClamp #IonChannels #DrugDiscovery #Electrophysiology #Sophion

Our new neuroscience brochure is now available for you to download for insight into: 💡Panel of models with increasing complexity and translational relevance: • Cell lines for central and peripheral nervous system targets. • Primary neuronal cultures, such as dissociated cortical, trigeminal or DRG. • CNS drug discovery to understand the effects of test compounds on brain slice tissue. • Human iPSC-derived neurons. 💡Range of assay methodologies to help you investigate the mechanism of action for pre-clinical compounds, confirm compound effects, address the neurotoxicity of compounds and assess the effects of compounds on a range of excitability parameters: • Heterologous cell lines and integrative assays. • Selectivity and safety profiling of lead compounds and IND candidates. • Translational assays: central and peripheral neuronal firing, and native ion channel screening assays. 💡Studying ion channels on the lysosomal membrane. 💡CNS drug discovery to understand the effects of test compounds on brain slice tissue. 📄Case study: Multi-assay high-throughput repurposing screen for rare epilepsy mutation in KCNC1 gene. As a specialist preclinical drug discovery CRO, we pride ourselves on delivering high quality data, on time and on budget. Find out more about our neuroscience services and download the brochure: https://hubs.la/Q02GXJCC0 Contact us to request a meeting or quote: https://hubs.la/Q02GXhnX0 #neuroscience #drugdiscovery #cro #ionchannels #lifesciences #cns #electrophysiology

#AlzheimersDisease (AD) is a progressive #neurodegenerative #disorder that impairs behavior, memory and thinking. AD has two pathological hallmarks: #NeurofibrillaryTangles (NFT) of hyperphosphorylated #tau protein and #AmyloidBeta (Aβ) plaques. The accumulation of Aβ plaques is thought to be the key event in AD #pathogenesis and hence, the #drugdesign is focused on preventing formation of or disruption of the Aβ plaques. Several drugs, including small molecules and antibodies, have been developed to treat AD. Although these therapeutics were effective #invitro, most of them were found to be ineffective #invivo. This suggests that the Aβ assemblies in vivo possibly differ from those in vitro. Hence, there is a need to obtain #PhysiologicallyRelevant (in vivo) structures of the Aβ plaque for their use in drug design. In an interesting article, published in #naturecommunications, the authors from the #UniversityOfLeeds, #FrancisCrickInstitute and #AstraZeneka (UK) report the native structures of Aβ plaques in #MammalianBrain. To reveal the native 3D architecture of Aβ plaques in mice brains, the authors employed #ElectronCryotomography (cryoET) and #cryogenic #CorrelatedLightAndElectronMicroscopy (cryoCLEM). Their data showed a complex and diversified architecture of Aβ plaques including #fibrils, rods, and branched #amyloid. The authors also determined in-tissue 3D architecture of amyloid plaques using cryoEM. Their work sheds light on how mutations affect the structure in Aβ fibrils. Insights obtained from this work will be beneficial in understanding #DiseaseProgression, #Pathology #imaging , identification of #novel #DrugTargets and #DrugDiscovery to combat Alzheimer’s disease. For further information, please see the article at following link.    https://lnkd.in/d8wGj3NY   #AlzheimersDisease, #Tauopathies, #DrugDiscovery, #AmyloidFibril, #AnimalModel, #CryoET